Brian Champion | CSO
Akamis Bio

Brian Champion, CSO, Akamis Bio

Brian Champion obtained his PhD from McGill University, Montreal, Canada and is currently Chief Scientific Officer at PsiOxus Therapeutics Ltd, Oxford, UK where he has been leading the scientific development of novel oncolytic virus-based, Tumor-Specific Immunogene (T-SIGn) therapies for the treatment of cancer for the past 8 years.   He was previously Executive Director and Head of Immunology for Pfizer's Vaccine Immunotherapeutics Research Unit in La Jolla, California. Prior to this he was Site Head for Pfizer Vaccine Research in the UK, and before joining Pfizer he was Chief Scientific Officer for Lorantis and Celldex in Cambridge (UK). Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years.

Appearances:



Festival of Biologics Day 1 @ 14:40

T-SIGn vector-mediated reprogramming of the tumor microenvironment drives T-cell dependent immunotherapy for solid tumors

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers